Everything you knew about bioabsorbable polymer stents has changed. MiStent is the only stent which is tailored to the vessel response, optimising patient outcomes by ensuring sustained drug release long after its polymer coating is absorbed, thanks to its unique crystalline drug release technology.
MiStent is a registered trademark of Micell Technologies, Inc.
Unique Crystalline Drug Delivery
MiStent SES delivers sirolimus, in a crystalline form, to the tissue. This unique method of delivery allows for a sustained drug presence that is maintained after the polymer is absorbed
Gradual, Linear and Long-Term Elution Profile
Unique to MiStent SES sirolimus is maintained in a microcrystalline matrix and elution is sustained up to 9 months, as opposed to a conventional DES which utilises an amorphous form of drug and a much shorter elution period.
Rapid Polymer Absorption with Sustained Drug Presence
Thin Strut Design
Outstanding Acute Performance
Rapid Strut Coverage
Uncovered struts are predictive of late stent thrombosis1
0% Stent Thrombosis (Definite and Probable) at 4 years in both DESSOLVE I and II studies
Lansky, A., Device and Clinical Program Highlights: Micell Presentation at TCT 2015.
Low Late Lumen Loss
Low Late Lumen Loss Progression
Slow Progression of TLR over Time
Proven Long Term Safety
Guidewire compatibility 0.014” (0.35mm).
2.5, 2.75, 3.0mm diameters are compatible with a 5F (1.7mm) Guiding Catheter,
3.5mm diameters are compatible with a 6F (2.0mm) Guiding Catheter